• To evaluate the safety of increasing doses of CS-747 (a loading dose during PCI and 29 to 34 days of once-daily maintenance dosing) by observing the rate of noncoronary artery bypass graft (non-CABG)-associated significant bleeding. [ Time Frame: 30-35 days ]
  

• To evaluate the safety and efficacy of increasing doses of CS-747 by observing the following endpoints at 30 to 35 days after PCI: non–CABG-associated major bleeding, major adverse cardiovascular events, and non–CABG major plus minor bleeding. [ Time Frame: 30-35 days ]
  

Inclusion Criteria:

• Patients must be candidates for elective or urgent PCI with intended coronary stenting.
• Men or non-pregnant women (that is, postmenopausal women, women who are surgically sterile, or women of childbearing potential who have a negative urine or serum pregnancy test) who are greater than or equal to 18 and less than or equal to 75 years of age.

Exclusion Criteria:

• Patients must not have planned PCI procedure as initial treatment for an acute ST-elevation acute myocardial infarction (STEMI)
• Patients must not be receiving or will receive oral anticoagulation therapy that cannot be safely discontinued for the duration of the study
• Patients must not have cardiogenic shock or severe congestive heart failure
• Patients must not have active internal bleeding or history of bleeding diathesis
• Patients must not have prior history of hemorrhagic cerebrovascular accident (CVA) or nonhemorrhagic CVA within 2 years of enrollment